Cargando…

Effects and potential mechanism of atorvastatin treatment on Lp-PLA2 in rats with dyslipidemia

INTRODUCTION: The effects of statins on lipoprotein-associated phospholipase A2 (Lp-PLA2) are controversial, and the present study aimed to investigate whether atorvastatin could reduce Lp-PLA2 in rats with dyslipidemia. MATERIAL AND METHODS: A high-fat and high-cholesterol diet was prescribed to pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Dongdan, Cai, Anping, Xu, Rulin, Mai, Zhuocheng, Zhou, Yingling, Zeng, Fanfang, Li, Liwen, Mai, Weiyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2017
Materias:	Experimental Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5949919/ https://www.ncbi.nlm.nih.gov/pubmed/29765452 http://dx.doi.org/10.5114/aoms.2017.69494

Ejemplares similares

Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats
por: Zheng, Dongdan, et al.
Publicado: (2015)

Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement
por: Zheng, Dongdan, et al.
Publicado: (2014)

Lipoprotein-Associated Phospholipase A2 (Lp-PLA(2)): A Novel and Promising Biomarker for Cardiovascular Risks Assessment
por: Cai, Anping, et al.
Publicado: (2013)

Atorvastatin Treatment of Rats with Ischemia-Reperfusion Injury Improves Adipose-Derived Mesenchymal Stem Cell Migration and Survival via the SDF-1α/CXCR-4 Axis
por: Cai, Anping, et al.
Publicado: (2013)

SDF-1α upregulation by atorvastatin in rats with acute myocardial infarction via nitric oxide production confers anti-inflammatory and anti-apoptotic effects
por: Qiu, Ruofeng, et al.
Publicado: (2012)

Baseline LDL-C and Lp(a) Elevations Portend a High Risk of Coronary Revascularization in Patients after Stent Placement
por: Cai, Anping, et al.
Publicado: (2013)

Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population
por: Cai, Anping, et al.
Publicado: (2015)

Effects of rosuvastatin combined with fasudil therapy on rabbits with dyslipidemia
por: Li, Zhiming, et al.
Publicado: (2015)

Lipoprotein(a): A Promising Marker for Residual Cardiovascular Risk Assessment
por: Cai, Anping, et al.
Publicado: (2013)

Lp-PLA2 Inhibition—The Atherosclerosis Panacea?
por: Karakas, Mahir, et al.
Publicado: (2010)

Lp-PLA(2) Inhibitors for the Reduction of Cardiovascular Events
por: Steen, Dylan L., et al.
Publicado: (2013)

Lp-PLA2 levels in HIV-infected patients
por: Díaz-Pollán, Beatriz, et al.
Publicado: (2014)

Genetic invalidation of Lp-PLA(2) as a therapeutic target: Large-scale study of five functional Lp-PLA(2)-lowering alleles
por: Gregson, John M, et al.
Publicado: (2016)

Association Lp-PLA2 Gene Polymorphisms with Coronary Heart Disease
por: Ma, Sha, et al.
Publicado: (2022)

Synergistic effects of atorvastatin and rosiglitazone on endothelium protection in rats with dyslipidemia
por: Zhang, Wei-Li, et al.
Publicado: (2014)

Increased Lipoprotein-associated phospholipase A2 activity portends an increased risk of resistant hypertension
por: Li, Zhiming, et al.
Publicado: (2016)

The Relationship between Intracarotid Plaque Neovascularization and Lp (a) and Lp-PLA2 in Elderly Patients with Carotid Plaque Stenosis
por: Sun, Chang, et al.
Publicado: (2022)

Association of spironolactone treatment and arterial stiffness and cardiovascular disease in hypertensive patients
por: Zeng, Fanfang, et al.
Publicado: (2019)

Lp-PLA(2), a new biomarker of vascular disorders in metabolic diseases
por: De Stefano, Alessandro, et al.
Publicado: (2019)

Association between Lp-PLA2 and coronary heart disease in Chinese patients
por: Yang, Li, et al.
Publicado: (2017)

The changes of Lp-PLA2 in patients with gestational diabetes and its clinical significance
por: Wang, Guo-Hua, et al.
Publicado: (2021)

Homocysteine and Lp-PLA2 levels: Diagnostic value in coronary heart disease
por: Wu, Linlin, et al.
Publicado: (2023)

Rho-GTPase and Atherosclerosis: Pleiotropic Effects of Statins
por: Cai, Anping, et al.
Publicado: (2015)

New Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a)
por: Kim, Kyung An, et al.
Publicado: (2023)

Prehypertension-Associated Elevation in Circulating Lysophosphatidlycholines, Lp-PLA(2) Activity, and Oxidative Stress
por: Kim, Minjoo, et al.
Publicado: (2014)

Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids
por: Jackisch, Laura, et al.
Publicado: (2018)

Identification of Inflammation-Related Biomarker Lp-PLA2 for Patients With COPD by Comprehensive Analysis
por: Deng, Mingming, et al.
Publicado: (2021)

Interaction and potential mechanisms between atorvastatin and voriconazole, agents used to treat dyslipidemia and fungal infections
por: Xun, Tianrong, et al.
Publicado: (2023)

Genome-Wide Association Study of Lp-PLA(2) Activity and Mass in the Framingham Heart Study
por: Suchindran, Sunil, et al.
Publicado: (2010)

Association of Lp-PLA(2) Mass and Aysmptomatic Intracranial and Extracranial Arterial Stenosis in Hypertension Patients
por: Wang, Yan, et al.
Publicado: (2015)

Lp-PLA(2) activity and mass and CRP are associated with incident symptomatic peripheral arterial disease
por: Fatemi, Shahab, et al.
Publicado: (2019)

On the present and future role of Lp-PLA(2) in atherosclerosis-related cardiovascular risk prediction and management
por: Fras, Zlatko, et al.
Publicado: (2020)

Sequencing of Lp-PLA2-encoding PLA2G7 gene in 2000 Europeans reveals several rare loss-of-function mutations
por: Song, K, et al.
Publicado: (2012)

Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A(2 )(Lp-PLA(2 )): a review
por: Silva, Isis T, et al.
Publicado: (2011)

Lp‐PLA(2), Plaque Inflammation and Lesion Development Vary Fundamentally Between Different Vascular Sites
por: Marsche, Gunther
Publicado: (2015)

Lp-PLA2 as a biomarker and its possible associations with SARS-CoV-2 infection
por: Dua, Pamila, et al.
Publicado: (2022)

The association between circulating Hcy and Lp-PLA2 levels and poststroke depression: A meta-analysis
por: Tao, Yongjun, et al.
Publicado: (2023)

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)
por: Deshmukh, Harshal A., et al.
Publicado: (2012)

The lpGBT production testing system
por: Guettouche, N, et al.
Publicado: (2022)

Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial
por: Kimura, Genjiro, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vr6frvutmpiik6rrafa6o9783l